Newsletter
|
It’s Elizabeth here with the first edition of Co-Founders’ Corner. Earlier this month, the FDA Psychopharmacologic Drugs Advisory Committee rejected Lykos Therapeutics' proposal for MDMA-assisted therapy for PTSD. While this is disappointing, it is only a recommendation; the official vote will happen in August.
Despite the findings, we believe the research does support MDMA’s safety and efficacy when administered by properly trained therapists in controlled settings.
As a leading psychedelic therapy training organization, we have witnessed firsthand the transformative potential of MDMA-assisted therapy in treating PTSD through their work on clinical trials. Psychedelic therapies have the potential to alleviate suffering for millions of individuals with PTSD, addictions, mood disorders, and a host of other conditions.
We continue collaborating with policymakers and prioritize patient safety, therapist competency, and ethical standards. We look forward to the FDA’s decision, which is expected on August 12, 2024.
Join us for a lively debrief of the FDA’s decision:
August 13th 2024 | 4PM ET
Thanks and have a great day!
Elizabeth Nielson, Fluence Co-Founder
All attendees will receive free access to our on-demand Introduction to MDMA-assisted Therapy Research course.
Enthea, a healthcare benefits manager, is modernizing workplace benefits with ketamine-assisted psychedelic (KAP) therapy coverage.
By joining Enthea, you become part of their provider network and can expand your practice. As an Enthea provider, you receive 20-30% off our full certificate course on Psychedelic Therapy Integration (PTI) and Ketamine-Assisted Psychotherapy (KAP).
You can sign up to Enthea here.
Great news if you're unsure about applying for the upcoming Psychedelic Therapy and Integration Course—we’ve waived the $100 application fee. All licensed mental health practitioners are eligible to apply.
Core Certification Course
Psychedelic Therapy and Integration (PTI)
August 7, 2024 – September 11, 2024
Psychedelic Therapy and Integration (PTI)
September 25, 2024 – October 30, 2024
Apply before September 18, 2024
Advanced Certification Course
After completion of the core course, advance to these courses:
Ketamine-Assisted Psychotherapy (KAP)
September 17, 2024 – December 10, 2024
Apply before September 10, 2024
Psychedelic Harm Reduction and Integration (PHRI)
September 19, 2024 –December 5, 2024
Apply before September 12, 2024
Ask about our August PTI + KAP Bundle! Receive a 13% discount if you take both courses together.
Our co-founder Dr. Elizabeth Nielson has contributed to a groundbreaking paper published in JAMA Network Open, which addresses key ethics and policy issues related to the clinical integration of psychedelic therapies.
Fluence Co-Founder Contributes to Groundbreaking Paper on Ethics and Policy in Psychedelic Clinical Care
Read the full press release here
